BACKGROUND: Vascular damage caused by cerebral ischemia leads to edema, hemorrhage formation, and worsened outcomes in ischemic stroke patients. Therapeutic interventions need to be developed to provide vascular protection. The purpose of this review is to identify the pathophysiologic processes involved in vascular damage after ischemia, which may lead to strategies to provide vascular protection in ischemic stroke patients. SUMMARY OF COMMENT: The pathologic processes caused by vascular injury after an occlusion of a cerebral artery can be separated into acute (hours), subacute (hours to days), and chronic (days to months). Targets for intervention can be identified for all 3 stages. Acutely, superoxide is the predominant mediator, followed by inflammatory mediators and proteases subacutely. In the chronic phase, proapoptotic gene products have been implicated. CONCLUSIONS: Pharmacological agents designed to target specific pathologic and protective processes affecting the vasculature should be used in clinical trials of vascular protection after acute ischemic stroke.
BACKGROUND:Vascular damage caused by cerebral ischemia leads to edema, hemorrhage formation, and worsened outcomes in ischemic strokepatients. Therapeutic interventions need to be developed to provide vascular protection. The purpose of this review is to identify the pathophysiologic processes involved in vascular damage after ischemia, which may lead to strategies to provide vascular protection in ischemic strokepatients. SUMMARY OF COMMENT: The pathologic processes caused by vascular injury after an occlusion of a cerebral artery can be separated into acute (hours), subacute (hours to days), and chronic (days to months). Targets for intervention can be identified for all 3 stages. Acutely, superoxide is the predominant mediator, followed by inflammatory mediators and proteases subacutely. In the chronic phase, proapoptotic gene products have been implicated. CONCLUSIONS: Pharmacological agents designed to target specific pathologic and protective processes affecting the vasculature should be used in clinical trials of vascular protection after acute ischemic stroke.
Authors: Ibolya Rutkai; Prasad V G Katakam; Somhrita Dutta; David W Busija Journal: Am J Physiol Heart Circ Physiol Date: 2014-07-25 Impact factor: 4.733
Authors: Germán Torregrosa; Fernando J Pérez-Asensio; María C Burguete; María Castelló-Ruiz; Juan B Salom; Enrique Alborch Journal: Exp Brain Res Date: 2007-01 Impact factor: 1.972
Authors: Y R Kim; E Tejima; S Huang; D N Atochin; G Dai; E H Lo; P L Huang; A Bogdanov; B R Rosen Journal: Magn Reson Med Date: 2008-10 Impact factor: 4.668
Authors: Matthew C Loftspring; Jeremiah McDole; Aigang Lu; Joseph F Clark; Aaron J Johnson Journal: J Cereb Blood Flow Metab Date: 2008-10-01 Impact factor: 6.200